Assuntos
Inibidores da Captação Adrenérgica/efeitos adversos , Agressão , Transtorno do Deficit de Atenção com Hiperatividade/tratamento farmacológico , Hostilidade , Propilaminas/efeitos adversos , Adolescente , Inibidores da Captação Adrenérgica/administração & dosagem , Cloridrato de Atomoxetina , Transtorno do Deficit de Atenção com Hiperatividade/complicações , Humanos , Masculino , Propilaminas/administração & dosagemRESUMO
Tensions exist across the primary-secondary care interface between GPs and hospital prescribing services. Repeat prescribing arrangements are a good focus for audit, as a patient started by the hospital on a treatment will tend to stay on it after discharge, with knock-on costs for primary care. Cost-effectiveness improvements in prescribing practice have included a significant reduction in hospital prescribing of 'loss-led' oral nitrates in favour of generic equivalents and the adoption as standard of the most cost-effective of the new proton pump inhibitors.
Assuntos
Prescrições de Medicamentos , Auditoria Médica , Serviço de Farmácia Hospitalar/normas , Continuidade da Assistência ao Paciente , Inglaterra , Medicina de Família e Comunidade , Relações Interprofissionais , Comitê de Farmácia e Terapêutica , Projetos Piloto , Medicina EstatalRESUMO
We report a case of a male infant who presented with congenital anomalies and was found to have a de novo deletion in the terminal region of the long arm of chromosome 9. He died at the age of 17 weeks of cardiorespiratory failure owing to RSV positive bronchiolitis. A review of previously published reports documented one previous report of a patient with a deletion of (9)(q34.3) and multiple congenital anomalies. Comparison with the previously reported case suggests that the phenotype observed constitutes a clinically recognisable pattern of malformations.
Assuntos
Anormalidades Múltiplas/genética , Deleção Cromossômica , Cromossomos Humanos Par 9 , Bandeamento Cromossômico , Feminino , Humanos , Lactente , Masculino , FenótipoRESUMO
The efficacy of fluorescent green light phototherapy was compared with that of blue light phototherapy in the treatment of full-term infants with hemolytic disease and jaundice caused by ABO incompatibility. The efficacy of the treatment was expressed as actual (milligrams per hour) and quantum (milligrams per hour per square centimeter per megawatt) efficiency, taking into account the differential emission of energy from the green versus the blue fluorescent tubes. No statistically significant difference in the rate of serum bilirubin photodegradation was found between the two groups after treatment for 84.6 +/- 14.1 hours versus 81.5 +/- 14.2 hours with the green and the blue phototherapy, respectively. These results, coupled with the known effects of the blue light on the genetic apparatus of mammalian cells, support the application of the green light phototherapy for the treatment of neonatal hyperbilirubinemia caused by ABO incompatibility.
Assuntos
Icterícia Neonatal/terapia , Fototerapia/instrumentação , Humanos , Recém-NascidoRESUMO
A total of 262 neonates were treated with green (350-650 nm) or blue (300-600 nm) light phototherapy for a similar length of time. There was no significant difference in the rate of bilirubin photodegradation between the groups.
